LY303870, a Centrally Active Neurokinin-1 Antagonist with a Long Duration of Action
Satish Iyengar(Eli Lilly (United States)), Rosa Maria A. Simmons, Réjean Couture(Université de Montréal), Sylvie Boucher, D. L. LI, Douglas A. Schober, Philip A. Hipskind, Mary Jeanne Kallman, J. A. Nixon, Donald R. Gehlert(Eli Lilly (United States)), David R. Helton, Karen L. Lobb
Cited by 58
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Kinin receptors in pain and inflammation
|European Journal of Pharmacology|2001|465
Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms <sup>1</sup>
|The FASEB Journal|1990|443
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization
|Trends in Pharmacological Sciences|1988|358